DHR · Earnings call · 2026Q3T · Full report

Segment Revenue Performance

DANAHER CORP /DE/ · 2026-10-21 · Importance 31 · Surprise 32

Biotechnology core revenue increased 5%; bioprocessing grew toward the upper end of mid-single digits, while discovery and medical declined low single digits. Life Sciences core revenue increased 4.5%, with Pall applied filtration and instruments each growing mid-single digits and consumables growing low single digits. Diagnostics core growth excluding respiratory revenue was 7%, but respiratory revenue reduced reported segment core growth to 50 basis points; clinical Diagnostics grew mid-single digits and Cepheid non-respiratory molecular diagnostics grew low double digits.